Literature DB >> 9787743

Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984.

C M Beard1, S C Waring, P C O'Brien, L T Kurland, E Kokmen.   

Abstract

OBJECTIVE: To compare the frequency of use of nonsteroidal anti-inflammatory drugs (NSAIDs) among 302 incident cases of Alzheimer's disease (AD) and age- and sex-matched control subjects.
DESIGN: We undertook a retrospective case-control study, using the resources of the Rochester Epidemiology Project.
MATERIAL AND METHODS: In ongoing studies of dementia in Rochester, Minnesota, we identified all incident cases of AD with onset between 1980 and 1984. From among all Rochester residents who received care at Mayo Clinic Rochester during those years, we selected one age- (within 3 years) and sex-matched control subject. For this study, exposure to a prescription NSAID was defined as prescribed use for 7 or more days during the 2-year window of time encompassing the year of onset and the year before onset among cases and the corresponding index year and the year prior for control subjects.
RESULTS: The odds ratio (OR) for exposure, as described, to a prescription NSAID versus no exposure to any NSAID was 0.79 (95% confidence interval [CI], 0.45 to 1.38); the OR was 1.00 (95% CI, 0.52 to 1.92) for women and 0.40 (95% CI, 0.13 to 1.29) for men. Similarly, the overall OR for aspirin exposure versus no NSAID exposure was 0.90 (95% CI, 0.54 to 1.50).
CONCLUSION: These data are suggestive but not confirmatory of a protective effect of NSAIDs for AD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9787743     DOI: 10.4065/73.10.951

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  27 in total

1.  CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase.

Authors:  J Tan; T Town; T Mori; Y Wu; M Saxe; F Crawford; M Mullan
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

Review 2.  Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies.

Authors:  Mahyar Etminan; Sudeep Gill; Ali Samii
Journal:  BMJ       Date:  2003-07-19

3.  Microglial activation induces cell death, inhibits neurite outgrowth and causes neurite retraction of differentiated neuroblastoma cells.

Authors:  Gerald Münch; Jovana Gasic-Milenkovic; Sladjana Dukic-Stefanovic; Björn Kuhla; Katrin Heinrich; Peter Riederer; Henri J Huttunen; Hank Founds; Gangadharan Sajithlal
Journal:  Exp Brain Res       Date:  2003-03-05       Impact factor: 1.972

Review 4.  Medications and diet: protective factors for AD?

Authors:  Claudia H Kawas
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Jul-Sep       Impact factor: 2.703

Review 5.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

Authors:  Tony Wyss-Coray; Joseph Rogers
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

6.  Mefenamic Acid Attenuates Chronic Alcohol Induced Cognitive Impairment in Zebrafish: Possible Role of Cholinergic Pathway.

Authors:  Venugopalan Rajesh; Mohanan Mridhulmohan; Subramanian Jayaseelan; Palanivel Sivakumar; Vellaiyachamy Ganesan
Journal:  Neurochem Res       Date:  2018-05-23       Impact factor: 3.996

Review 7.  Involvement of Fc receptors in disorders of the central nervous system.

Authors:  Eitan Okun; Mark P Mattson; Thiruma V Arumugam
Journal:  Neuromolecular Med       Date:  2009-10-21       Impact factor: 3.843

Review 8.  Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Authors:  Eiron Cudaback; Nikolas L Jorstad; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Biochem Pharmacol       Date:  2014-01-13       Impact factor: 5.858

Review 9.  Inflammatory mechanisms in neurodegeneration.

Authors:  Michael R Nichols; Marie-Kim St-Pierre; Ann-Christin Wendeln; Nyasha J Makoni; Lisa K Gouwens; Evan C Garrad; Mona Sohrabi; Jonas J Neher; Marie-Eve Tremblay; Colin K Combs
Journal:  J Neurochem       Date:  2019-03-27       Impact factor: 5.372

10.  Current therapeutic options for Alzheimer's disease.

Authors:  Alberto Lleó
Journal:  Curr Genomics       Date:  2007-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.